Advertisement
AMGN vs JNJ
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and JNJ is a Buy.
AMGN in upward trend: 10-day moving average crossed above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 44 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 26 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 67 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 46%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.297) is normal, around the industry mean (-1.421). P/E Ratio (28.386) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
JNJ in upward trend: 10-day moving average broke above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Oscillator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
AMGN | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | 2 | |
SMR RATING 1..100 | 15 | 37 | |
PRICE GROWTH RATING 1..100 | 10 | 19 | |
P/E GROWTH RATING 1..100 | 26 | 7 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (75) in the Pharmaceuticals Major industry is in the same range as AMGN (79) in the Biotechnology industry. This means that JNJ’s stock grew similarly to AMGN’s over the last 12 months.
JNJ's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as AMGN (3) in the Biotechnology industry. This means that JNJ’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is in the same range as JNJ (37) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to JNJ’s over the last 12 months.
AMGN's Price Growth Rating (10) in the Biotechnology industry is in the same range as JNJ (19) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's P/E Growth Rating (7) in the Pharmaceuticals Major industry is in the same range as AMGN (26) in the Biotechnology industry. This means that JNJ’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | JNJ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 59% |
| Stochastic ODDS (%) | 2 days ago 46% | 2 days ago 52% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 45% |
| MACD ODDS (%) | N/A | 2 days ago 40% |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 47% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 50% |
| Advances ODDS (%) | 9 days ago 62% | 10 days ago 46% |
| Declines ODDS (%) | 5 days ago 47% | 5 days ago 43% |
| BollingerBands ODDS (%) | 2 days ago 51% | 2 days ago 41% |
| Aroon ODDS (%) | 2 days ago 56% | 2 days ago 44% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while JNJ’s FA Score has 3 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- JNJ’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 6 bullish TA indicator(s).
- AMGN’s TA Score: 5 bullish, 4 bearish.
- JNJ’s TA Score: 6 bullish, 4 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а -1.20% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +1.11% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
Reported Earning Dates
AMGN is expected to report earnings on Feb 09, 2027.
JNJ is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then GSK could also see price increases.
| Ticker / NAME | Correlation To JNJ | 1D Price Change % | ||
|---|---|---|---|---|
| JNJ | 100% | +1.43% | ||
| GSK - JNJ | 53% Loosely correlated | -0.16% | ||
| ABBV - JNJ | 53% Loosely correlated | +1.07% | ||
| NVS - JNJ | 52% Loosely correlated | +0.38% | ||
| MRK - JNJ | 48% Loosely correlated | -0.14% | ||
| AMGN - JNJ | 47% Loosely correlated | +0.03% | ||
More | ||||